DUBLIN--(BUSINESS WIRE)--Sep 11, 2018--The "Global B-cell Non Hodgkin Lymphoma Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The Global B-Cell Non-Hodgkin Lymphoma Drugs Market to grow at a CAGR of 7.52% during the period 2018-2022.

Global B-cell non-Hodgkin Lymphoma Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the retail sales of B-cell non-Hodgkin lymphoma drugs across the globe.

According to the report, one driver influencing this market is the growing government initiatives. Increasing government initiatives such as Cancer Breakthrough 2020 are driving the growth of the market across the globe. One trend affecting this market is the strong pipeline. The count of pipeline in the B-cell non-Hodgkin lymphoma drugs market is increasing rapidly which is expected to boost the growth of the market.

Further, the report states that one challenge affecting this market is the high cost of treatment. The high cost of treatment is impeding the growth of the global B-cell non-Hodgkin lymphoma drugs market.

Key vendors

Biogen F. Hoffmann-La Roche Merck Novartis Spectrum Pharmaceuticals

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

PART 05: MARKET SIZING

PART 06: FIVE FORCES ANALYSIS

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY CATEGORY

Comparison by category Small molecules Biologicals Market opportunity by category

PART 09: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison Market opportunity

PART 10: CUSTOMER LANDSCAPE

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

Strong pipeline Strategic alliances Advanced technologies

PART 14: VENDOR LANDSCAPE

Overview Landscape disruption

PART 15: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors

For more information about this report visit https://www.researchandmarkets.com/research/g6spcv/global_bcell_non?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005681/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Lymphoma Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/11/2018 01:22 PM/DISC: 09/11/2018 01:22 PM

http://www.businesswire.com/news/home/20180911005681/en